Glioblastoma multiforme (GBM) is a highly invasive cancer with a high recurrence rate. The prognosis of GBM patients remains poor, even after standard surgical resection combined with chemoradiotherapy. Thus, there is an urgent need for new therapeutic targets in GBM. In recent years, microRNAs have received considerable attention due to their important role in tumor development and progression. In this study, we investigated the role of miR-129-5p and miR-129-5p/ZFP36L1 axis in GBM tumorigenesis. Analysis of GSE103228 microarray data from the GEO database showed that miR-129-5p was significantly downregulated in GBM vs. normal brain tissues. Quantitative reverse transcription PCR analysis of miR-129-5p expression in seven GBM cell lines (LN229, A172, U87, T98G, U251, H4, and LN118) vs. normal human astrocytes (NHA) showed miR-129-5p was significantly downregulated in GBM cells. Overexpression of miR-129-5p in LN229 and A172 cells significantly suppressed cell proliferation, migration, invasion, and colony-forming ability. Target Scan analysis identified ZFP36L1 as the target of miR-129-5p. UALCAN dataset analysis found that ZFP36L1 was significantly upregulated in GBM vs. normal brain tissues, and high ZFP36L1 expression was positively associated with poor survival of GBM patients. Western blot analysis demonstrated that ZFP36L1 was significantly upregulated in seven GBM cell lines vs. NHA. Overexpression of miR-129-5p in LN229 and A172 cells significantly inhibited ZFP36L1 mRNA and protein expression, while overexpression of ZFP36L1 in LN229 and A172 cells reversed miR-129-5p-mediated inhibition on GBM tumorigenesis. Our results revealed an important role of miR-129-5p in the negative regulation of ZFP36L1 expression in GBM, suggesting new candidates for targeted therapy in GBM patients.
INTRODUCTION
Among all human brain tumors, glioma accounts for the largest category of primary brain tumors, and glioblastoma multiforme (GBM) is the most malignant tumor. GBM accounts for about 14 .7% of all primary and metastatic tumors of the brain [1] . The incidence of GBM was increasing year by year, and the incidence of non-GBM was gradually decreased [2] . In the United States and Europe, the incidence of GBM is 2 to 3 per 100,000 people [3] . GBM is the most malignant type of astrocytoma, and the clinical manifestations are headache, convulsions, and psychiatric symptoms. Another typical features of GBM are fast growth and high malignancy. Although surgery combined with radiation therapy and chemotherapy has been widely used for the treatment of GBM patients, the prognosis is still very poor with a median survival about 12 months, a 2-year survival rate of only 26-33%, and a 5-year survival rate of about 4-5% [2, 4] . In order to provide a better treatment strategy for GBM patients, it is necessary to continue to identify other potential therapeutic targets for GBM and to clarify the underlying mechanism.
MicroRNAs (miRNAs) are a class of non-coding single-stranded RNAs of ~22 nucleotides encoded by endogenous genes and participated in the regulation of post-transcriptional gene expression in plants and animals [5] . Collective evidences have demonstrated that miRNAs play a crucial regulatory roles in the development, differentiation, and apoptosis in normal cells, as well as a pro-carcinogenic or anti-pro-carcinogenic role in cancer formation and progression [6, 7] . Molecularly, miRNAs can target the 5'-or 3'-untranslated region of the target genes and subsequently regulate cellular functions, such as tumor proliferation, migration, and invasion. Abnormal expression of miRNAs were found in chronic 5 lymphocytic leukemia [8] , breast cancer [9] , non-small cell lung cancer [10] , pancreatic cancer [11] , and liver cancer [12] . Recent studies further showed that the expression of miRNAs was involved in glioma development [13] [14] [15] [16] [17] . Overexpression of miR-148a or miR-378-3p suppressed the GBM proliferation, migration, and invasion by targeting integrin subunit alpha 9 (ITGA9) and transmembrane 4 superfamily member 17 (tetraspanin 17), respectively [18, 19] . In addition, the expression of miRNAs was found to be associated with chemoresistance of tumor cells or tumor stem cells [20] [21] [22] . Upregulation of miR-145 enhanced the sensitivity of GBM stem cells to demethoxycurcumin, and overexpression of miR-29a significantly inhibited the proliferation of GBM stem cells. In the recent years, miR-129-5p have received considerable attention as drivers of Alzheimer's disease [23] , osteogenesis [24] , and intervertebral disk degeneration [25] . Furthermore, miR-129-5p was reported to be involved in the tumorigenesis of gastric [26] [27] [28] , pancreatic [29] , laryngeal [30] , prostate [31] , lung [32] , and hepatocellular carcinoma [33] . Recent reports demonstrated that miR-129-5p was able to regulate the proliferation and invasion of GBM cells lines [16, 34] . However, despite these studies, the specific regulatory mechanisms of miR-129-5p in glioma remain unclear and require further investigation.
ZFP36 ring finger protein-like 1 (ZFP36L1) belongs to the member of ZFP36 RNA-binding protein family [35] , which contains two standard repetitive zinc finger motifs (CCCH). The CCCH motif binds to the AU-rich elements (AREs) in the 3'-UTRs of target RNA, resulting in instability of the targeted mRNA [36] . It's reported that ZFP36L1 was functionally involved in posttranscriptional regulation of bile acid metabolism of hepatocytes, myogenesis, and lymphocyte development [37] [38] [39] [40] . Disruption of ZFP36L1 expression in 6 mice led to lethality on embryonic day 11 [41] . Increasing the level of ZFP36L1 inhibited cell growth in lung carcinoma and colorectal cancer cell lines [42, 43] . However, little is known about the biological role of ZFP36L1 and its regulatory factors (such as miRNAs) in GBM tumorigenesis.
In this study, differentially expressed miRNAs between GBM and normal tissues were analyzed and miR-129-5p was found abnormally down-regulated in GBM tissues and GBM cell lines. Decreased miR-129-5p expression was accompanied by the up-regulation of ZFP36L1. Subsequently, we confirmed that overexpression of miR-129-5p inhibited proliferation, migration, invasion, and colony-forming ability of GBM cells LN229 and A172. Furthermore, we identified that ZFP36L1 was the downstream target gene of miR-129-5p. Overexpression of miR-129-5p inhibited the expression of ZFP36L1. Moreover, forced expression of ZFP36L1 significantly restored miR-129-5p-mediated inhibition of GBM hallmarks, including tumor proliferation, migration, and colony-forming ability. Hence, our results provide a pivotal role of the miR-129-5p/ZFP36L1 axis in the GBM tumorigenesis and sheds a new light on further targeted therapy against malignant GBM tumors.
MATERIALS AND METHODS

Analysis of microarray data
The miRNA and mRNA expression profile (GSE103228) was selected from GEO database (https://www.ncbi.nlm.nih.gov/geo/). The profile contained both mRNA and miRNAs expression of 5 human GBM and 5 normal brain tissues. Analysis of miRNAs expression was performed based on the GPL18058 platform (Exiqon miRCURY LNA microRNA array, 7th generation). The differentially expressed miRNAs in GBM samples were further analyzed by 7 GEO's R language analysis tool (http://www.ncbi.nlm.nih.gov/geo/geo2r/). Adjusted P-values were applied based on Benjamini-Hochberg method to minimize the false discovery rate. To determine the deregulated miRNAs in the GBM samples, the cut-off values were defined as the fold change >2 and adjusted P-value <0.05. After deleting the unknown miRNA and missing information, we found that miR-129-5p was the top 3 miRNAs and was selected for further analysis.
Identification of miRNA-targeting genes
The target genes of the deregulated miRNA (miR-129-5p) was identified using Target Scan (http://www.targetscan.org/vert_72/), which is dedicated to the analysis of mammalian miRNA targeting genes. Based on the cumulative weighted context++ score, ZFP36L1 was one of the top 25 target candidates for miR-129-5p. After literature search, pre-analysis of TCGA, and removal of proteins with unknown function, ZFP36L1 was the promising candidate gene and was selected for further analysis.
UALCAN dataset analysis
The UALCAN (http://ualcan.path.uab.edu/index.html) database provides an easy access to publicly available cancer transcriptome data (namely, TCGA and MET500 transcriptome sequencing). In this study, UALCAN was used to identify biomarkers and in silico validate potential genes of interest. In addition, gene expression (ZFP36L1) and patient survival information based on gene expression were analyzed in the UALCAN dataset to explore its impact on the prognosis of patients with GBM.
Cell culture
Normal human astrocyte cells (NHA) and human GBM cell lines (LN229, A172, U87, T98G, U251, H4 and H118) were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). These cells were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, United States) containing 10% fetal bovine serum (FBS, Invitrogen) in a humidified atmosphere of 5% CO2 at 37 °C.
RNA isolation and quantitative reverse transcription PCR
Total RNAs were extracted from cultured cells as described previously [44] . In brief, total 
Western blot analysis
Western blot analysis was performed as described previously [45] . In brief, cells were lysed with lysis buffer (Beyotime, Shanghai, China) containing 1 mmol/L PMSF. After centrifugation at 14,000 x g for 10 min at 4°C, the extracted proteins were resuspended, and the concentrations were measured using the bicinchoninicacid (BCA) protein assay kit (Beyotime). Equal amounts (30 μg) of protein were resolved by using SDS-PAGE and electro-transferred onto the PVDF membrane (Millipore). The immunoblots were then blocked with 5% fat-free milk for 1 h, and further incubated overnight with primary antibodies against ZFP36L1 (1:1000 dilution, ab42473, Abcam, USA) and GAPDH (1:3000 dilution, ab181602, Abcam, USA) at 4 °C. After incubation with peroxidase-conjugated secondary antibodies for 1 h, the blots were washed and then visualized using an electrochemiluminescence (ECL) detection kit (ThermoBiotech Inc, Rockford, IL, United States). The chemiluminescent signal on the blots was determined and quantified using densitometric software (Bio-Rad, California, United States).
Transfection
Transfections were performed using the Lipofectamine 3000 Reagent (Invitrogen) according to the manufacturer's instruction. For the transfection of miRNAs, 50 nmol/L of miR-129-5p mimics (5'-CUUUUUGCGGUCUGGGCUUGC-3') and/or miR-NC (5'-UUGUACUACACAAAAGUACUG-3') were used for each transfection well (6-well culture plate) containing 2 mL culture medium. After 48 h transfection, total RNAs and proteins were collected for further analysis. For the overexpression of ZFP36L1, 2x10 3 of LN229 and A172 cells were seeded onto 6-well plates. After overnight culture, the cells were transfected with 0.75 μg/mL of pcDNA3.1 (control) or pcDNA3.1-ZFP36L1 for 48 h. The transfection efficiency of ZFP36L1 was evaluated by qRT-PCR and Western blot analysis. In order to visualize and count the numbers of cells, cells were fixed with 4% paraformaldehyde at 4°C for 60 min. After washing twice with ice-cold PBS, cells were stained with impurity-free crystal violet for 2 min and imaged under a microscope.
Cell proliferation assay
Cell proliferation was determined using the Cell Counting Kit-8 (CCK-8) kit (Dojindo, Japan) by following the manufacturer's instructions. In brief, cells (3,000 cells/well) were transfected with NC, miR-NC, or miR-129-5p mimics and cultured in 96-well plates. After 0, 24, 48, and 72 h incubation, 100 μL of culture supernatant from each well was collected and transferred to another 96-well plates and then incubated with 10 μL of CCK-8 solution at 37 °C for 4 h. The absorbance was measured at 450 nm wavelength using spectrophotometry (BioTek, United States).
Wound healing assay
Cells were seeded in six-well plates and then treated with NC (transfection reagent control), miR-NC (miRNA sponge-negative scramble control), or miR-129-5p mimics. Linear scratch wounds were created on cell monolayers using a sterile 200 μL pipette tip, and the scratched areas were imaged at ×100 magnification using a Leica DMI3000B computer-assisted microscope (Leica, Buffalo Grove, United States). Images were captured at 0, 24, 48, and 72 h after scratching and analyzed using Image-Pro Plus v6.0 image analysis software (Media Cybernetics, Rockville, MD, United States). The remaining wound area was calculated to estimate the migration distance of the cells.
Matrigel invasion assay
Matrigel invasion assay was performed using Transwell plates (BD, Biosciences, United States). Transwell membrane inserts were precoated with Matrigel (BD), and the analyzed cells were appropriately seeded onto the upper compartment of the chamber. The bottom chamber contained complete RPMI-1640 medium, and the upper chamber contained serumfree medium. After 24 h incubation at 37 °C, cells on the Matrigel-coated upper surface were wiped off with a cotton swab, and the invaded cells throughout the filter were fixed and stained with Giemsa at 37 °C for 3 h. The images of invaded cells were photographed with a microscope (Leica) at × 100 magnification. For each membrane isolated from triplicate chambers, the number of invaded cells were counted in three randomly selected fields. The results were presented as a column graph with statistics.
Statistical analysis
All statistical analyses were performed using SPSS 20.0 software package (SPSS, Chicago, IL, United States). Data were expressed as the mean ± SD. Herein, χ2 test, Student's t test, and one-way ANOVA analysis was used for comparisons. P < 0.05 was considered statistically significant.
RESULTS
Down-regulated miR-129-5p expression in GBM tissues and cell lines
To evaluate the miR-129-5p expression profiles in GBM tissues, the microarray dataset (GSE103228) was used to examine whether miR129-5p expression was associated with GBM tumorigenesis. After analyzing 3,557 differentially expressed miRNAs, it was found that the expression of miR-129-5p was significantly downregulated in GBM tissues than normal brain tissues (p<0.005, Figure 1A ). Next, the decreased expression of miR-129-5p in GBM was further validated using normal human astrocytes (NHA) and 7 GBM cell lines, including LN229, A172, U87, T98G, U251, H4, and LN118. As shown in Figure 1B , miR-129-5p was abnormally down-regulated in all GBM cell lines with a reduction of approximately 60-90%, suggesting that miR-129-5p may play an important role in the tumorigenesis of GBM.
miR-129-5p inhibited the hallmarks of GBM
To explore the tumorigenic role of miR-129-5p in GBM, the two cell lines LN229 and A172 with the least expression of miR-129-5p cell lines were selected. We first overexpressed miR-129-5p in LN229 and A172 cells and examined whether miR-129-5p could affect the GBM proliferation, migration, invasion, and colony-forming abilities. Compared with non-treated control (NC), transfection with miRNA sponge-negative scramble control (miR-NC) did not alter the expression of miR-129-5p in LN229 and A172 cells (Figure 2A) . Moreover, as compared to miR-NC group, the level of miR-129-5p was significantly increased to about 11.5-and 9.5-fold in LN229 and A172 cells, respectively. Next, CCK-8 assay was performed to examine whether miR-129-5p can affect the proliferation ability. Overexpression of miR-129-5p significantly inhibited the proliferation of LN229 and A172 cells after 72, 96, and 120 h of culture ( Figure 2B) , indicating that miR-129-5p was functionally involved in the tumor cell proliferation. Next, the miR-129-5p-mediated proliferation and migration inhibition was further examined by wound-healing assay, a classic method for comprehensive analysis of cell proliferation and migration. As shown in Figure 3A , the two control groups (NC and miR-NC) of LN229 and A172 cells exhibited strong and aggressive motility, but 13 overexpression of miR-129-5p reduced the wound healing ability after 72 h of culture. The wound closure rates of miR-129-5p overexpression LN229 and A172 cells were significantly lower than that transfected with miR-NC at 24, 48, and 72 h (P<0.05; Figure 3B ). In addition to cell migration, strong colony-forming ability is the hallmarks of GBM. Thus, we examined whether miR-129-5p could affect the capacity of GBM cells to produce progeny, which analyzed by colony forming assay. The results showed that overexpression of miR-129-5p significantly inhibited the number of colony formation in both LN229 cells and A172 cells ( Figure 3C ). Taken together, results of CCK-8 assay, wound-healing assay, and colonyforming assay suggested that miR-129-5p can suppress the GBM hallmarks, including tumor proliferation, migration, and colony-forming ability.
ZFP36L1 as a hypothetical target of miR-129-5p
To further investigate the underlying mechanism of miR-129-5p-mediated inhibition of tumor proliferation, migration and colony-forming ability, the Target Scan bioinformatics database was used and identified ZFP36L1 as the potential target genes of miR-129-5p ( Figure 4A ). To further validate the relationship between miR-129-5p and ZFP36L1, UALCAN was used to examine the expression of ZFP36L1 in GBM samples. As shown in Figure 4B , the expression of ZFP36L1 in GBM samples was significantly higher than that in normal brain samples (p<0.0005). In addition, survival analysis showed that patients with higher expression of ZFP36L1 had significantly increased risk of death ( Figure 4C ). Next, the expression of ZFP36L1 was confirmed in NHA and GBM cell lines. As shown in Figure 4D , ZFP36L1 was significantly up-regulated to 2-6.5 fold in 7 GBM cell lines, suggesting that miR-129-5p was negatively correlated with ZFP36L1 in GBM. To further validate this hypothesis, miR-129-5p mimics was overexpressed in LN229 and A172 cells, and the expression of ZFP36L1 was determined by quantitative RT-PCR. As shown in Figure 4E , overexpression of miR-129-5p significantly inhibited the ZFP36L1 mRNA expression in either LN229 or A172 cells (p<0.05). Results of Western blotting analysis ( Figure 4F ) further supported the hypothesis that miR-129-5p overexpression resulted in the suppression of ZFP36L1 protein expression.
Taken together, these results indicated that miR-129-5p negatively regulated the expression of ZFP36L1 in GBM.
Overexpression of ZFP36L1 reverses the inhibitory effect of miR-129-5p
Next, we examined whether miR-129-5p-regulated ZFP36L1 expression is involved in GBM proliferation, migration, and colony forming ability. At first, above miR-129-5poverexpressed LN229 and A172 cells were further transfected with pcDNA3.1-ZFP36L1 to increase the level of ZFP36L1, and the cells in the control group were transfected with pcDNA3.1 vector. The expression of ZFP36L1 was determined by qRT-PCR and Western blot analysis ( Figure 5A ). Compared to pcDNA3.1 control group, transfection with pcDNA3.1-ZFP36L1 successfully enhanced the mRNA and protein levels of ZFP36L1 in both LN229 and A172 cells (p<0.05). Afterwards, we examined whether miR-129-5pmediated tumor proliferation inhibition could be reversed by increased expression of ZFP36L1. As shown in Figure 5B , ZFP36L1 overexpression significantly restored the miR-129-5p-mediated proliferation inhibition in LN229 and A172 cells (p<0.05), suggesting that ZFP36L1 played a crucial role in the GBM proliferation. We next examined the role of ZFP36L1 in cell migration, invasion, and colony forming ability. Results of wound-healing assay showed that ZFP36L1 overexpression increased tumor migration ability ( Figure 6A ).
Compared to the empty vector transfected cells, the open wound area in ZFP36L1 expression
cells were significantly reduced in 24, 48, and 72 h culture in LN229 and A172 cells (p<0.05, Figure 6B ). Furthermore, miR-129-5p-mediated inhibition in colony-forming ability were restored by ZFP36L1 overexpression (Figure 6C ). Collectively, these experiments indicated that miRNA-129-5p negatively regulated ZFP36L1 expression to affect the proliferation, migration, and colony-forming abilities in LN229 and A172 GBM cells.
DISCUSSION
Although there are multiple treatments for GBM, GBM is currently the most common primary malignant brain tumor with a poor prognosis. In the past few years, attention has been paid to the role of miRNAs in the development, diagnosis, and prognosis of gliomas. In this study we demonstrated that miR-129-5p and miR-129-5p-regulated ZFP36L1 target gene may be involved in GBM. We found that miR-129-5p was dramatically down-regulated in GBM tissues and 7 GBM cell lines. Re-expression of miR-129-5p suppressed the hallmarks of GBM, including cell proliferation, migration, and the colony-forming ability. Furthermore, we identified that ZFP36L1 was the downstream target of miR-129-5p and was responsible for miR-129-5p-mediated tumor proliferation, migration, and colony-forming ability.
Overexpression of ZFP36L1 in miR-129-5p-overexpressing tumor cells successfully restored all the hallmarks of GBM. Thus, our study suggested that during the development of GBM, miR-129-5p expression was reduced and led to higher expression of ZFP36L1, thus GBM became more proliferative, migrative, and has a higher colony forming ability. Moreover, restoring the expression of miR-129-5p effectively suppressed the GBM tumorigenesis.
MiR-129-5p has recently received extensive attention as a tumor suppressor. In gastric 16 cancer, miR-129-5p was found to attenuate tumor progression by targeting HMGB1 [27] , WWP1 [28] , ADAM9 [46] , SLC2A3 [47] , COLA1 [48] , and IL-8 [49] . In addition, miR-129-5p was recently identified to regulate cell invasion and metastasis in lung cancer [32] , hepatocellular carcinoma [50] , pancreatic [29] , and prostate cancer [31] . Gao et al. found that the expression of miR-129-5p levels were significantly decreased in human prostate cancer tissues, and downregulation of miR-129-5p increased ETV1 expression. Overexpression of ETV1 attenuated miR-129-5p induced cell proliferation [31] . On the other hand, Gu et al. found that DNA (cytosine-5)-methyltransferase 3A (DNMT3A), a tumor suppressor in glioma, was negatively regulated by miR-129-5p [51] . Overexpression of DNMT3A partially attenuates miR-129-5p inhibited cell proliferation, suggesting that other unidentified downstream targets of miR-129-5p may affect GBM proliferation and even affect other hallmarks of GBM, such as migration, and colony-forming ability. In this study, miR-129-5p was found to be significantly downregulated in LN229, A172, U87, T98G, U251, H4, and LN118 cells as well as GBM tissue samples. To further explore the specific biologic role of miR-129-5p in GBM, the two cell lines LN229 and A172 with the lowest expression of miR-129-5p were selected to restore the expression of miR-129-5p. Notably, miR-129-5p overexpression not only inhibited cell proliferation and migration, but also suppressed its colony-forming ability. These results indicated that miR-129-5p can be considered as a tumor suppressor during GBM development and that miR-129-5p may be used as a potential diagnostic and prognostic biomarker for GBM patients in future.
In addition to the association with tumorigenesis, miR-129-5p was implicated in many diseases. Study by Yang et al. suggested that dysregulation of miR-129-5p might contribute to the development of intervertebral disc degeneration by targeting BMP2 expression [25] . In patients with intervertebral disc degeneration, miR-129-5p was downregulated along with BMP2 upregulation. Overexpression of miR-129-5p apparently increased the survival of neural progenitor cells, whereas downregulation of miR-129-5p increased the degree of apoptosis. Moreover, the restored BMP2 expression reversed the effect of miR-129-5p. On the other hand, miR-129-5p was recently suggested to play a crucial role in the protection of cardiac function [52] . In the chronic heart failure rat model, miR-129-5p transfection not only improved heart function and hemodynamic parameters, but also attenuated oxidative stress and inflammation factors. In addition, another study by Zeng et al. demonstrated that miR-129-5p may be a potential candidate for the treatment of Alzheimer's disease [23] .
Overexpression of miR-129-5p promoted neuronal cell proliferation, and suppressed apoptosis and degraded the inflammatory reaction. These studies suggest that miR-129-5p is involved in different aspects of biological functions and deserves further investigation.
It is difficult to develop efficient treatment against GBM because GBM is characterized by many dysregulated pathways. Currently, maximal surgical resection combined with postoperative radiotherapy and chemotherapy are the standard treatment of GBM. However, chemoresistance is the typical hallmarks of recurrent GBM. More than 90% of GBM relapsed at the primary tumor site, and 5% of GBM occurred to multiple lesions after treatment. Ma et al. demonstrated that miR-129-5p was able to inhibit the stemness and chemoresistance of non-small cell lung cancer cells [53] . Overexpression of miR-129-5p suppressed the ability of sphere formation and the expression of stemness makers, including Oct4, Sox2, and Nanog in non-small cell lung cancer cells. On the other hand, miR-129-5p/HMGB1 axis [54] and NONHSAT101069/miR-129-5p axis [55] were found to regulate the radiosensitivity and epirubicin resistance of breast cancer cells, respectively. In this study, the colony-forming assay was conducted to indirectly investigate the stemness ability of GBM cells. Remarkably, our results showed that miR-129-5p significantly suppressed the colony-forming ability of LN229 and A172 GBM cells. This implied that miR-129-5p might affect GBM stemness. It warrants further investigation in the future.
The RNA-binding protein ZFP36L1 is able to directly bind to 3′-UTRs of their target mRNAs and promote mRNA decay. However, less studies focused on the role of ZFP36L1 in the tumorigenesis. Loh et al. suggested that ZFP36L1 may function as a tumor suppressor [56] .
Forced expression ZFP36L1 inhibited cell proliferation in bladder and breast cancer cells.
Moreover, a different study by Zindy's team demonstrated that ZFP36L1 was upregulated in hepatocellular carcinoma, implying that ZFP36L1 may be oncogenic in liver cancer [57] . In this study, we found that ZFP36L1 was highly expressed in GBM cell lines and tissues samples. Remarkably, GBM patients with higher expression of ZFP36L1 were associated with poor survival probability. Different from the study of Loh et al. in bladder and breast cancer cells [56] , ZFP36L1 overexpression in GBM cells not only enhanced cell proliferation, but also increased cell migration and colony-forming ability. This suggested that ZFP36L1 may play different biological roles in different tumors, and ZFP36L1 may become a potential target for GBM treatment. This deserves further investigation.
The limitation of this study was that the number of GBM patients was not very large.
Although current study found that miR-129-5p and ZFP36L1 were associated with the hallmarks of GBM, it remains unclear whether the expression of miR-129-5p and ZFP36L1 19 were associated with overall survival, disease-free survival, and recurrence-free survival of GBM patients. Thus, further prospective studies should be conducted to investigate the association of miR-129-5p and ZFP36L1 with survival and to make comprehensive adjustments with several important prognostic confounders.
CONCLUSION
In conclusion, the present finding revealed a tumor suppressor role of miR-129-5p/ZFP36L1 axis in GBM proliferation, migration, and colony-forming ability. Crucially, ZFP36L1 expression in GBM was negatively regulated by miR-129-5p and associated with poor survival probability. Altogether, our study not only identified a new tumor suppressor role of miR-129-5p/ZFP36L1 axis in GBM tumorigenesis, but also provided potential targets for treating GBM patients in the future.
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